title: Glucose concentration in the dialysate does not contribute to lipid profiles in patients undergoing CAPD.
abstract: The aim of this study was to investigate lipid profiles in patients with end-stage renal disease receiving hemodialysis (HD), continuous ambulatory peritoneal dialysis (CAPD), or no dialysis (nondialytic treatment group, NT), and to analyze the association between dyslipidemia in CAPD patients with glucose-containing dialysate dosages. Lipid profiles were determined in 64 NT patients, 62 HD patients, and 180 CAPD patients at a single time point. NT patients' samples were collected following hospitalization due to renal failure. HD and CAPD patients' samples were collected after 3 months of dialysis. The association between lipid profiles of 180 CAPD patients and glucose-containing dialysate was analyzed using Pearson methods; 76.56% of NT patients, 66.13% of HD patients, and 72.22% of CAPD patients had dyslipidemia. Compared with NT patients, CAPD patients had significantly altered levels of cholesterol, triglycerides, high-density lipoprotein, apolipoproein (Apo)-A1, and Apo-E (p < 0.05), but unchanged levels of low-density lipoprotein or Apo-B. There was no correlation between the three different concentrations of glucose in the dialysate with the lipid profile of CAPD patients. We concluded that patients on CAPD exhibit dyslipidemia, and that different concentrations of glucose in the dialysate do not affect lipid profiles in these patients.
authors.affiliation: Department of Nephrology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China. drzhengli2009@126.com
authors.forename: Zheng
authors.initials: Z
authors.lastname: Li
authors.forename: Huang
authors.initials: H
authors.lastname: Fengxian
mesh_terms: D000328:Adult; D000368:Aged; D015992:Body Mass Index; D001835:Body Weight; D048909:Diabetes Complications / Q000097:blood / Q000139:chemically induced; D015314:Dialysis Solutions / Q000009:adverse effects*; D050171:Dyslipidemias / Q000097:blood / Q000139:chemically induced*; D005260:Female; D005947:Glucose / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000628:therapy; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D010531:Peritoneal Dialysis, Continuous Ambulatory
chemical_list: D015314:Dialysis Solutions; D008055:Lipids; D005947:Glucose